Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 32.4474
- Book/Share 0.8269
- PB 231.7201
- Debt/Equity 49.2176
- CurrentRatio 0.7602
- ROIC 0.1793
- MktCap 328744704000.0
- FreeCF/Share 8.7019
- PFCF 21.3679
- PE 78.4368
- Debt/Assets 0.5133
- DivYield 0.0343
- ROE 0.9559
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ABBV | Citigroup | Buy | Neutral | -- | $205 | May 14, 2025 |
| Initiation | ABBV | Cantor Fitzgerald | -- | Overweight | -- | $210 | April 22, 2025 |
| Resumed | ABBV | BofA Securities | -- | Neutral | -- | $191 | Dec. 10, 2024 |
| Downgrade | ABBV | Daiwa Securities | Outperform | Neutral | -- | $180 | Dec. 5, 2024 |
| Initiation | ABBV | Bernstein | -- | Market Perform | -- | $203 | Oct. 17, 2024 |
News
U.S. politicians dump this pharma stock days before Trump's drug price order
Published: May 12, 2025 by: Finbold
Sentiment: Neutral
Summary ⚈ Two U.S. lawmakers sold AbbVie shares shortly before Trump's drug price-cutting announcement, raising concerns about potential insider knowledge. ⚈ Trump's May 13 executive order targets up to 80% reductions in drug costs, directly impacting companies like AbbVie.
Read More
Cerevel Therapeutics Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV
Published: May 09, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud.
Read More
Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc.(ABBV) of a Class Action Lawsuit and an Upcoming Deadline
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
Read More
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join - Contact The Gross Law Firm
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit – ABBV
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Read More
ABBV LAWSUIT ALERT: Levi & Korsinsky Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=147234&wire=1 or contact Joseph E. Levi, Esq.
Read More
JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects?
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Both JNJ and ABBV expect their sales and profits to improve in 2025.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 6, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud.
Read More
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights – ABBV
Published: May 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
Read More
Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 – ABBV
Published: May 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
Read More
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join – Contact The Gross Law Firm
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Read More
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Final Trades: Netflix, Abbvie, iShares U.S. Industrials ETF and Sherwin Williams
Published: April 29, 2025 by: CNBC Television
Sentiment: Neutral
The Fast Money team just dropped their Final Trades — find out what's catching their eye now!
Read More
Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 – ABBV
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
Read More
Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next?
Published: April 29, 2025 by: Benzinga
Sentiment: Negative
AbbVie Inc. ABBV is trading higher Tuesday. The stock has been in an uptrend.
Read More
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
Published: April 29, 2025 by: PRNewsWire
Sentiment: Neutral
– RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults – Also known as temporal arteritis, GCA is the most common vasculitis affecting adults in Western countries 2 – This marks the ninth approved indication for RINVOQ in the U.S., across rheumatology, gastroenterology, and dermatology1 NORTH CHICAGO, Ill. , April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).1 This comes after the …
Read More
Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV
Published: April 29, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud.
Read More
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc. (ABBV) Urged to Join Class Action – Contact The Gross Law Firm to Learn More
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Read More
3 Dividend Stocks to Buy and Hold for the Next Decade
Published: April 28, 2025 by: The Motley Fool
Sentiment: Positive
Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.
Read More
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Should Investors Be Worried About Dividend King AbbVie?
Published: April 28, 2025 by: The Motley Fool
Sentiment: Neutral
Nearly everything looked great with AbbVie's (ABBV 3.10%) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune disease drugs Skyrizi and Rinvoq.
Read More
Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results
Published: April 27, 2025 by: Seeking Alpha
Sentiment: Positive
As always, AbbVie did not disappoint me with its financial results for the first quarter of 2025. It beat the analyst consensus estimates by a wide margin, thanks to the strong performance of its oncology, neuroscience, and immunology franchises. So, total sales of Rinvoq and Skyrizi reached $5.14 billion in the first three months of 2025, increasing by 65.8% year-on-year.
Read More
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
Published: April 26, 2025 by: The Motley Fool
Sentiment: Positive
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts.
Read More
Drugmaker AbbVie says tax reform, not tariffs, would drive U.S. manufacturing
Published: April 25, 2025 by: Market Watch
Sentiment: Neutral
AbbVie Inc. took a little shot at the Trump administration's trade policy, as the drugmaker said Friday that rather than tariffs, tax reform is the key to boosting U.S. manufacturing.
Read More
AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.
Read More
AbbVie Q1 Earnings Review: Typically Strong Performance, Aesthetics Aside
Published: April 25, 2025 by: Seeking Alpha
Sentiment: Positive
AbbVie Inc.'s Q1 earnings show an 8.4% revenue increase, driven by strong performance in immunology, neuroscience, and oncology divisions, with Skyrizi and Rinvoq leading growth. Despite Humira's patent expiry, AbbVie successfully transitioned to new revenue sources, has upgraded its full-year EPS estimates, and maintains a robust dividend yield of over 3.6%. ABBV is expanding into the obesity drug market with a promising amylin analog, potentially doubling its share price value if successful, although it is very early days.
Read More
AbbVie Stock Rises on Stronger-Than-Expected Results, Profit Outlook Lift
Published: April 25, 2025 by: Investopedia
Sentiment: Positive
AbbVie (ABBV) on Friday reported first-quarter results that came in above analysts' estimates, and lifted its full-year profit guidance.
Read More
ABBV Earnings Beat, Exposure to Tariffs, ABBV & UNH Options Trades
Published: April 25, 2025 by: Schwab Network
Sentiment: Positive
David Kaplan says AbbVie (ABBV) shows "unusually strong growth compared to peers." While he notes parts of its business is exposed to tariffs, the pharmaceutical and medical device industries are typically resilient to macro headwinds, and he believes AbbVie can withstand most.
Read More
AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
AbbVie (ABBV) Q1 Earnings and Revenues Beat Estimates
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.31 per share a year ago.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Mr. Robert A. Michael CPA
- Employees 55000